Clinical significance of serum PR3-ANCA in ulcerative colitis

Clinical significance of serum PR3-ANCA in ulcerative colitis - Clinical significance of serum PR3-ANCA in ulcerative colitis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039174

Enrollment

150

Registered

2020-01-16

Start date

2019-07-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Between April 2016 and June 2019, patients with ulcerative colitis that underwent colonoscopy and serum PR3-ANCA measurement within the span of 1 week.

Exclusion criteria

Exclusion criteria: Cases excluded were patients ages 0 to 5 or with a complication that could be serum positive for PR3-ANCA or MPO-ANCA such as autoimmune disease, chronic extraintestinal inflammatory disease, malignant tumor, or hyperthyroidism, and patients being treated or with a history of treatment with TNF alpha inhibitors, (infliximab and adalimumab), which have the potential to cause drug-induced ANCA-associated vasculitis. Also excluded from analysis were patients being treated or with a history of treatment with steroids or immunoregulators and serum PR3-ANCA levels below the detection limit.

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the relationship between ulcerative colitis activity and serum PR3-ANCA.	—

Secondary

Measure	Time frame
To evaluate the background factor and prognosis of serum PR3-ANCA positive in ulcerative colitis.	—

Countries

Japan

Contacts

Public ContactYUKI AOYAMA

Kagawa Prefectural Central Hospital Gastroenterology

yublue.med@gmail.com087-811-3333

Outcome results